Avalo Therapeutics, Inc. (NASDAQ: AVTX)

Avalo Therapeutics, Inc. is a clinical stage biotechnology company dedicated to developing interleukin‑1β (IL‑1β)‑based therapies for immune‑mediated inflammatory diseases.

Its lead product candidate, abdakibart (AVTX‑009), is a humanized monoclonal antibody that binds IL‑1β with high affinity and neutralizes its activity, thereby inhibiting downstream inflammatory pathways.

Abdalikibart is currently being evaluated in the Phase 2 LOTUS trial, a randomized, double‑blind, placebo‑controlled study enrolling approximately 250 adults with moderate to severe hidradenitis suppurativa across sites in the United States, Canada, Europe, and Australia.

Enrollment in the LOTUS trial was completed in October 2025 and topline data are expected in the second quarter of 2026, which will inform planning for potential Phase 3 studies.

Beyond HS, the company is exploring additional indications for abdakibart and seeking to in‑license or acquire complementary preclinical and clinical assets that target similar inflammatory pathways to broaden its pipeline.

The company’s strategy for increasing stockholder value includes advancing its pipeline toward regulatory approval, pursuing opportunistic out‑licensing of rights, and seeking to acquire or develop complementary assets that treat immune‑mediated inflammatory diseases.

Avalo Therapeutics, Inc. has not yet generated product revenue and is financed primarily through equity offerings and existing cash reserves.

The company anticipates future revenue from the commercial sale of abdakibart (AVTX‑009) following regulatory approval and from potential out‑licensing of the compound or related indications to third parties.

Under its worldwide exclusive license from Eli Lilly and Company, Avalo Therapeutics is responsible for development and commercialization and would owe milestone and royalty payments to Lilly upon achieving regulatory and sales milestones.

Given its clinical‑stage status, Avalo Therapeutics currently maintains limited internal capabilities for sales, distribution, and marketing and would rely on third‑party partners or develop its own infrastructure upon commercialization.

The firm’s cash position is supported by the proceeds from prior equity offerings and the AlmataBio transaction completed in the first quarter of 2024.

• no_segments_reported.

Avalo Therapeutics, Inc. operates in a highly competitive segment of the biotechnology industry focused on IL‑1β inhibition and treatments for hidradenitis suppurativa.

Approved IL‑1β blockers such as Novartis AG’s ILARIS (canakinumab) and Changchun GeneScience Pharmaceuticals Co., Ltd.’s antibody represent direct competition, while several other companies—including Sunshine Guojian Pharmaceutical Co Ltd and TavoTek—are advancing non‑biosimilar anti‑IL‑1β antibodies in clinical development.

In the HS therapeutic landscape, the company competes with established biologics like AbbVie Inc.’s adalimumab (anti‑TNF‑α), Novartis’ secukinumab (anti‑IL‑17A), UCB’s bimekizumab (dual anti‑IL‑17A/F), and numerous investigational programs targeting JAK, BTK and dual IL‑1α/β pathways.

Market estimates indicate that the global hidradenitis suppurativa market could exceed $10 billion by 2035, with a U. S. prevalence of approximately 0.7‑1.2% and a diagnosed‑and‑treated population projected to rise from 1.0 million in 2024 to 1.6 million by 2035.

Avalo Therapeutics differentiates itself through the high affinity and potency of abdakibart, its potential best‑in‑class profile, and the prospect of obtaining up to 12 years of biologics reference product exclusivity in the United States after approval, which could provide a regulatory advantage despite the expiration of the underlying composition‑of‑matter patent.

The company also benefits from a lean organizational structure of 33 full‑time employees, with 18 focused on research and development, allowing it to allocate capital efficiently toward clinical advancement.

Avalo Therapeutics, Inc. intends to serve patients with moderate to severe hidradenitis suppurativa, their treating physicians, dermatology clinics, and the healthcare payers that cover biologic therapies.

This patient population includes individuals covered by government programs such as Medicare, and Medicaid as well as those with private commercial insurance.

Given the chronic nature of HS, the company also anticipates engagement with specialty pharmacy providers, and managed care organizations that administer high‑cost biologic treatments.

Despite available biologics, a substantial proportion of HS patients remain inadequately treated, highlighting the unmet medical need that Avalo Therapeutics aims to address.